U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H19NO2
Molecular Weight 233.3062
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXMETHYLPHENIDATE

SMILES

[H][C@@]1(CCCCN1)[C@H](C(=O)OC)C2=CC=CC=C2

InChI

InChIKey=DUGOZIWVEXMGBE-CHWSQXEVSA-N
InChI=1S/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3/t12-,13-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H19NO2
Molecular Weight 233.3062
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

CNS Activity

Curator's Comment: Dexmethylphenidate is a central nervous system (CNS) stimulant

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FOCALIN

Approved Use

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23.72 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.13 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
10.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
120.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
131.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
79.8 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.68 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.81 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.3 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Other AEs: Vomiting, Agitation...
Other AEs:
Vomiting
Agitation
Tremor
Hyperreflexia
Muscle twitching
Convulsions
Euphoria
Confusion
Hallucinations
Delirium
Sweating
Flushing
Headache
Hyperpyrexia
Tachycardia
Palpitations
Cardiac arrhythmias
Hypertension
Mydriasis
Mucosal dryness
Rhabdomyolysis
Sources: Page: p.11
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Disc. AE: Twitching, Anorexia...
AEs leading to
discontinuation/dose reduction:
Twitching (1%)
Anorexia (1%)
Insomnia (1%)
Tachycardia (1%)
Insomnia (1.8%)
Sources: Page: p.7
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Disc. AE: Cardiac disorders, Stroke...
Other AEs: Increased blood pressure, Heart rate increased...
AEs leading to
discontinuation/dose reduction:
Cardiac disorders (grade 3-5)
Stroke (grade 3-5)
Myocardial infarction (grade 3-5)
Seizures
Raynaud's phenomenon
Other AEs:
Increased blood pressure
Heart rate increased
Psychotic symptom (grade 3-5)
Psychotic symptom
Manic symptom
Aggression
Growth suppression
Priapism
Erection prolonged
Vascular disorders
Visual disturbance
Sources: Page: p.1
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Disc. AE: Feeling jittery, Anorexia...
AEs leading to
discontinuation/dose reduction:
Feeling jittery (1.8%)
Anorexia (1.2%)
Anxiety (1.2%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Agitation
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Cardiac arrhythmias
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Confusion
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Convulsions
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Delirium
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Euphoria
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Flushing
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hallucinations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Headache
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hyperpyrexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hyperreflexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hypertension
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Mucosal dryness
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Muscle twitching
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Mydriasis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Palpitations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Rhabdomyolysis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Sweating
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Tachycardia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Tremor
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Vomiting
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Anorexia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Insomnia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Tachycardia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Twitching 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Insomnia 1.8%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Aggression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Erection prolonged
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Growth suppression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Heart rate increased
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Increased blood pressure
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Manic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Priapism
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Psychotic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Vascular disorders
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Visual disturbance
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Raynaud's phenomenon Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Seizures Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Psychotic symptom grade 3-5
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Cardiac disorders grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Myocardial infarction grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Stroke grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Anorexia 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Anxiety 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Feeling jittery 1.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
weak
yes
PubMed

PubMed

TitleDatePubMed
Dexmethylphenidate--Novartis/Celgene. Focalin, D-MPH, D-methylphenidate hydrochloride, D-methylphenidate, dexmethylphenidate, dexmethylphenidate hydrochloride.
2002
Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats.
2003 Feb
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
2004 Winter
A double-blind, placebo-controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder.
2004 Winter
Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.
2005 Jul
Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core.
2005 Mar
ADHD in adolescence and adulthood, with a special focus on the dopamine transporter and nicotine.
2006
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
2006
Dexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.
2006 Dec
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
2006 Jan
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
2006 Jul
Misuse of "study drugs:" prevalence, consequences, and implications for policy.
2006 Jun 9
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.
2006 Oct
[Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review].
2007
Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man.
2007 Dec
Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate.
2007 May 31
A randomized, double-blind, crossover study of once-daily dexmethylphenidate in children with attention-deficit hyperactivity disorder: rapid onset of effect.
2008
Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
2008 Jun
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
2008 May
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.
2009
Once-daily medications for the pharmacological management of ADHD in adults.
2009 Apr
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
2009 Aug
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.
2009 Jun 29
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
2009 Mar
Dexmethylphenidate for attention deficit hyperactivity disorder.
2009 Nov
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
2010 Apr
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
2010 Aug
Use of psychostimulants in patients with dementia.
2010 Oct
European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD.
2010 Sep 3
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.
2011 Jan 1
Patents

Sample Use Guides

Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5 mg/day (2.5 mg twice daily). Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration: Oral
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:45:05 GMT 2023
Edited
by admin
on Fri Dec 15 15:45:05 GMT 2023
Record UNII
M32RH9MFGP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXMETHYLPHENIDATE
INN   VANDF   WHO-DD  
INN  
Official Name English
Dexmethylphenidate [WHO-DD]
Common Name English
METHYLPHENIDATE D-THREO-FORM
MI  
Common Name English
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER, (.ALPHA.R,2R)-
Common Name English
METHYLPHENIDATE D-THREO-FORM [MI]
Common Name English
dexmethylphenidate [INN]
Common Name English
DEXMETHYLPHENIDATE [VANDF]
Common Name English
METHYL (2R)-PHENYL((2R)-PIPERIDIN-2-YL)ACETATE
Systematic Name English
Classification Tree Code System Code
WHO-VATC QN06BA11
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
NDF-RT N0000175729
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
NCI_THESAURUS C47795
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
WHO-ATC N06BA11
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
LIVERTOX 291
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
NDF-RT N0000175739
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
Code System Code Type Description
EVMPD
SUB30294
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
ChEMBL
CHEMBL827
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
WIKIPEDIA
DEXMETHYLPHENIDATE
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
MERCK INDEX
m7453
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY Merck Index
CAS
40431-64-9
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
IUPHAR
7554
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
RXCUI
352372
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY RxNorm
PUBCHEM
154101
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
LACTMED
Dexmethylphenidate
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
SMS_ID
100000092743
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
CHEBI
51860
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
DRUG BANK
DB06701
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
EPA CompTox
DTXSID70893769
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
DRUG CENTRAL
836
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
NCI_THESAURUS
C26642
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
INN
8289
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
DAILYMED
M32RH9MFGP
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
FDA UNII
M32RH9MFGP
Created by admin on Fri Dec 15 15:45:05 GMT 2023 , Edited by admin on Fri Dec 15 15:45:05 GMT 2023
PRIMARY
Related Record Type Details
BINDER->LIGAND
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC following oral administration of serdexmethylphenidate single moiety alone
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC INTRAVENOUS ADMINISTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC IN HEALTHY ADULT SUBJECTS
PHARMACOKINETIC